Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
InnovaBurn is a placental-derived extracellular matrix (ECM) medical device developed by Convatec for the management of various wound types, specifically optimized for partial-thickness second-degree burns. It is a xenograft manufactured using the proprietary TriCleanse Process, which decellularizes the placental tissue while preserving essential structural proteins. The device provides a biological scaffold that conforms and adheres to the wound site, requiring no special preparation or orientation. It is indicated for burns, traumatic lacerations, dehisced incisional wounds, pressure ulcers, venous ulcers, post-Mohs surgical wounds, and diabetic ulcers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on InnovaBurn.